Zealand’s dasiglucagon meets key endpoints in paediatric trial of severe hypoglycaemia

This article was originally published here

Invented and developed by Zealand Pharma, dasiglucagon is a potential first-in-class soluble glucagon analogue with a unique stability profile in a ready-to-use aqueous solution. Dasiglucagon is being developed

The post Zealand’s dasiglucagon meets key endpoints in paediatric trial of severe hypoglycaemia appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply